ADHD medications

Stimulants include methylphenidate-based and amphetamine-based medicines. They increase dopamine and norepinephrine signaling in circuits involved in attention, working memory, motivation, and impulse control, and they work on the day they are taken. Non-stimulants include atomoxetine, viloxazine ER, guanfacine ER, and clonidine ER; they are taken daily and build benefit over weeks. Bupropion is sometimes used off-label.

Across pediatric guideline data, stimulants have a larger average effect on core symptoms than the approved non-stimulants. Response is highly individual: roughly 40% respond to both methylphenidate and amphetamine families, while about 40% respond to only one. In the 14-month NIMH MTA trial, careful medication management and combined medication plus behavior therapy both outperformed behavior therapy alone or routine community care for core symptoms; more than 70% improved when the full methylphenidate dose range was tried. Combination care also helped some areas of daily functioning and allowed lower medication doses.

SOURCE · AAP CLINICAL PRACTICE GUIDELINE   SOURCE · NIMH MTA STUDY

A useful dose should make attention, task-starting, impulse control, and follow-through easier—not create euphoria or flatten personality. Benefit is often noticeable within days. Irritability, tearfulness, or hyperactivity as a short-acting dose wears off may be rebound; a prescriber may adjust timing, formulation, or the dose rather than simply raising it.

SOURCE · FDA RITALIN LABEL   SOURCE · LISDEXAMFETAMINE REVIEW   SOURCE · LISDEXAMFETAMINE PHARMACOLOGY REVIEW

Do not stop guanfacine or clonidine suddenly. Abrupt discontinuation can cause rebound hypertension with severe headache, agitation, tremor, or a racing heart. If several doses are missed, call the prescriber before restarting at the prior dose.

SOURCE · ATOMOXETINE FDA LABEL VIA DAILYMED   SOURCE · VILOXAZINE REVIEW   SOURCE · AAP GUIDELINE UPDATE

Stimulants commonly reduce appetite and can cause weight loss, stomachache, headache, dry mouth, sweating, jitteriness, sleep difficulty, palpitations, or rebound irritability. They raise blood pressure by about 2–4 mmHg and heart rate by about 3–6 beats per minute on average, although an individual rise can be larger. New or worsening tics, emotional flatness, tearfulness, or persistent appetite and sleep problems belong in the next prescriber conversation.

In children, stimulants can slow weight gain and, to a smaller degree, height gain. Long-term evidence suggests a small average adult-height difference of about 1–2 cm that may not fully catch up. Height and weight should be tracked on growth charts. Practical supports include breakfast before the dose takes effect, dinner after it wears off, calorie-dense snacks, and a consistent bedtime routine.

Before treatment, clinicians review personal and family cardiac history, blood pressure, pulse, height, weight, mood or mania, psychosis, tics, anxiety, substance use, and other medicines. A routine ECG or echocardiogram is not required for everyone; guidelines reserve testing for concerning cardiac history or examination findings, although practice varies. During treatment, blood pressure, pulse, sleep, appetite, weight, mood, tics, adherence, and diversion risk are reviewed regularly.

SOURCE · AAP GUIDELINE UPDATE   SOURCE · GROWTH AND CARDIOVASCULAR REVIEW   SOURCE · NIMH MTA STUDY

• Heart or neurologic emergency: chest pain, shortness of breath, fainting, a very fast or irregular heartbeat, sudden severe headache, one-sided weakness, speech trouble, or vision change needs urgent assessment.
• Psychiatric emergency: new hallucinations, paranoia, delusions, mania, severe aggression, or unsafe behavior needs same-day clinical help; use emergency services if danger is immediate.
• Priapism: a painful erection lasting more than four hours is an emergency. Fingers or toes that turn white, blue, or red, become numb or painful, or develop sores also need prompt review.
• Atomoxetine: itching, dark urine, yellow skin or eyes, right-upper-abdominal pain, or flu-like symptoms can signal rare liver injury.
• Suicidal thoughts or behavior: atomoxetine and viloxazine carry boxed warnings for children and adolescents. Atomoxetine trials found suicidal ideation in 0.4% of treated patients versus 0% on placebo; no completed suicides occurred. Call or text 988, contact the prescriber the same day, and use emergency services when there is a plan, intent, or immediate danger.

For suspected stimulant overdose, call Poison Control at 1-800-222-1222. Severe agitation, confusion, hallucinations, very high blood pressure, racing heart, chest pain, seizures, very high temperature, vomiting, or loss of consciousness calls for emergency care.

SOURCE · ATOMOXETINE FDA LABEL VIA DAILYMED   SOURCE · METHYLPHENIDATE MEDICATION GUIDE   SOURCE · AMPHETAMINE OVERDOSE CASE SERIES

All stimulant ADHD medications are Schedule II controlled substances because misuse and dependence are real risks. Prescribed daily use can produce physical dependence—feeling different on skipped days—which is not the same as addiction, meaning compulsive use despite harm. Addiction risk rises with higher-than-prescribed doses, use without ADHD, or snorting or injecting.

A meta-analysis of 30 studies estimated that about 17% of college students had misused prescription stimulants. Academic pressure was the most common motive, yet the reviewed studies did not show improved academic performance in people without ADHD; misuse was associated with poorer academic performance. Sharing or selling a prescription is illegal and can be dangerous.

• Store stimulants in a locked box or cabinet, out of sight and reach of children and visitors—not in a shared medicine cabinet.
• Never share, sell, or give away a pill. Keep it in the labeled prescription bottle and count pills periodically.
• Use a pharmacy take-back program for unused medicine, following local guidance.
• Avoid combining stimulants with alcohol or other drugs. Stimulants can mask intoxication, raising alcohol-poisoning risk; other stimulants increase heart and seizure risk.

If misuse is happening, tell the prescriber directly. Options can include a lower-abuse-potential formulation, a non-stimulant, shorter supplies, supervised dosing, or substance-use treatment. This is a health issue, not a moral failure.

SOURCE · STIMULANT MISUSE META-ANALYSIS SUMMARY   SOURCE · YOUTH MISUSE AND DIVERSION REVIEW   SOURCE · COLLEGE-STUDENT USE REVIEW

Interactions: stimulants, atomoxetine, and viloxazine must not be combined with MAOI antidepressants or started within 14 days of stopping one because of hypertensive-crisis risk. Decongestants, heavy caffeine or energy-drink use, other stimulants, blood-pressure medicines, serotonergic drugs, and some antidepressants can alter cardiovascular or serotonin-syndrome risk. Alcohol can mask intoxication with stimulants and worsen sedation with guanfacine or clonidine. Share the complete prescription, over-the-counter, supplement, and substance-use list.

Pregnancy and breastfeeding: evidence is limited, so decisions need an individualized risk–benefit discussion with the prescriber and obstetric clinician—ideally before trying to conceive. Methylphenidate pregnancy data are generally reassuring but not risk-free; some amphetamine data suggest small increases in preterm birth or low birth weight, with important confounding. Data for atomoxetine, guanfacine, clonidine, and viloxazine are sparse. During breastfeeding, published methylphenidate series show very low milk transfer, while amphetamines transfer more and require infant monitoring. Do not stop abruptly because of pregnancy.

Starting and stopping: stimulants are usually titrated from a low dose toward the lowest dose with useful benefit and tolerable side effects. They can generally be stopped without tapering, though symptoms return quickly and a brief period of tiredness, low mood, extra appetite, or sleep can follow. Atomoxetine and viloxazine do not cause classic withdrawal, but a taper may still be reasonable. Guanfacine and clonidine must be tapered.

Medication breaks: a planned break can be considered with a prescriber for stimulants, which work day by day; direct evidence is very low quality. Breaks are not appropriate for atomoxetine, viloxazine, guanfacine, or clonidine because their effect depends on regular dosing and the alpha-2 medicines can cause rebound hypertension. Driving, work, childcare, sports, camp, and other non-school needs still matter on break days.

SOURCE · AMPHETAMINE LABEL EXCERPTS   SOURCE · PREGNANCY AND LACTATION REVIEW   SOURCE · CRITICAL PREGNANCY REVIEW   SOURCE · NICE DRUG-HOLIDAY EVIDENCE REVIEW

Stimulants robustly reduce inattention, hyperactivity, and impulsivity in the short term and improve classroom behavior and daily functioning. Medication plus behavioral strategies often produces the broadest functional gains.

That does not prove medication changes long-term educational attainment or “normalizes” every outcome. Short trials show better seatwork, note-taking, and some quiz performance, while effects on standardized testing are smaller. At eight years, the MTA study found no differences among the original randomized treatment groups in grades, arrests, or psychiatric hospitalizations; early symptom trajectory predicted later outcomes better than the original assignment.

ADHD is a real, impairing neurodevelopmental condition, and diagnosis is also genuinely difficult because anxiety, depression, trauma, sleep loss, substance use, burnout, and ordinary distraction can look similar. A careful evaluation uses history across settings and the lifespan, collateral information when available, and assessment for look-alike conditions—not only a checklist or social-media quiz.

SOURCE · SCHOOL-PERFORMANCE REVIEW   SOURCE · MTA EIGHT-YEAR FOLLOW-UP   SOURCE · ADULT DIAGNOSIS AND PRESCRIBING TRENDS